Skip to Content

Louis L. Pisters, M.D.

Present Title & Affiliation

Primary Appointment

member, Division of Surgery Promotions Committee
Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1986 University of Western Ontario Faculty of Medicine, London, Ontario, Canada, MD, Medicine

Postgraduate Training

1991-1993 Fellowship in Urologic Oncology, Urologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Andrew von Eschenbach
1988-1991 Residency - Urology, Urology, University of Florida Medical Center/Gainesville V. A. Medical Center, Gainesville, FL, Dr. David Drylie
1986-1988 Internship - General Surgery, General Surgery, University of Florida Medical Center/Gainesville V. A. Medical Center, Gainesville, FL, Dr. Edward M. Copeland, III

Board Certifications

12/2005 American Board of Urology

Experience/Service

Academic Appointments

Associate Professor, Department of Urology, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2000-9/2006
Assistant Professor, Department of Urology, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 7/1994-9/2000
Faculty Associate, Department of Urology, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 7/1993-6/1994

Administrative Appointments/Responsibilities

member

Institutional Committee Activities

member, MDACC Infection Control Subcommittee, 1/2005-present
Urology Representative, Salary Review Committee of MDACC Faculty Senate, 1/2004-present
member, MDACC Medical/Surgical Materials Use Evaluation Committee, 1/2004-present
member, MDACC Organizing Committee Member, Urologic Oncology: Advances in Clinical Practice Conference, 1/2003-present

Honors and Awards

2005-2006 America's Top Doctors for Cancer, Castle Connolly Guide
1997 First Prize, T. Leon Howard Pyelogram House Case Presentation Award, 76th Annual Meeting of South Central Section of the American Urological Association
1997 Various Donors for Prostate Cancer Research Program Allocation, The University of Texas M. D. Anderson Cancer Center
1994 2nd Annual Meeting Resident's Essay Presentation Award, Houston Urologic Society
1984 Award in Medical Therapeutics, Merck, Sharp & Dohme
1983-1986 Dean's Honor List, University of Western Ontario Faculty of Medicine

Selected Publications

Peer-Reviewed Original Research Articles

1. Pisters LL. Cryotherapy for Prostate Cancer: Ready for Prime Time? Current Opinion in Urology 20:218-222, 5/2010.
2. Contreras AL, Punar M, Tamboli P, Tu SM, Pisters LL, Moran C, Czerniak BA, Guo CC. Mediastinal Germ Cell Tumors with an Angiosarcomatous Component: A Report of 12 Cases. Human Pathology 20(3):832-837, May 2010, 2/2010.
3. Levy, DA, Pisters LL, Jones JS. Primary cryoablation nadir prostate specific antigen and biochemical failure. J Urol 182(3):931-7, 9/2009.
4. Ward JF, Nakanishi H, Pisters LL, Babaian RJ, Troncoso P. Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU Int 104(4):490-7, 8/2009.
5. Davis, JW, Famat AM, Munsell M, Pettaway CA, Pisters, LL, Matin SF. Initial Experience Teaching Robot-Assisted Radical Prostatectomy to surgeons-in-training: Can Training be Evaluated and Standardized? British Journal of Urology International, 8/2009. e-Pub 8/2009.
6. Pisters LL, Leibovic D, Blute M, Zincke H, Sebo TJ, Slezak JM, Izawa J, Ward JF, Scott SM, Madsen L, Spiess PE Leibovich BC. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol 182(2):517-25, 8/2009.
7. Guo CC, Punar M, Contreras AL, Tu SM, Pisters LL, Tamboli P. Czerniak B. Testicular germ cell tumors with saracomatous components: an analysis of 33 cases. Am J Surg Pathol 33(8):1173-8, 8/2009.
8. Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaogli F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL. Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer 115(13):2872-80, 7/2009.
9. Parker PA, Pettaway CA, Babaian RJ, Pisters LL, Miles B, Fortier A, Wei Q, Carr DD, Cohen L. The effects of a presurgical stress management intervention for men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 27(19):3169-76, 7/2009.
10. Davis JW, Chang DW, Chevray P, Wang R, Shen Y, Wen S, Pettaway CA, Pisters LL, Swanson DA, Madsen LT, Huber N, Troncoso P, Babaian RJ, Wood CG. Randomized phase II trial evaluation of erectile function afer attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol 55(5):1135-43, 5/2009.
11. Gorbatiy V, Spiess PE, Pisters LL. The Growing Teratoma Syndrome: The Current Review of Literature. Indian Journal of Urology 25(2). e-Pub 4/2009.
12. Forrest JB, Clemens JQ, Finamore P, Leveillee R, Lippert M, Pisters LL, Touijer K, Whitmore K; American Urological Association. AUA best practice statement for the prevention of deep vein thrombosis in patients undergoing urologic surgery. J Urol 181(3):1170-7, 3/2009.
13. Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer 115(6):1310-7, 3/2009.
14. Tsavachidoiu D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type-and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 101(5):306-20, 3/2009.
15. Williams DH, Karpman E, Sander JC, Spiess PE, Pisters LL, Lipshultz LI. Pretreatment semen parameters in men with cancer. J Urol 181(2):736040, 2/2009.
16. Mathew P, Pisters LL, Wood CG, Papadopoulos JN, Williams DL, Thall PF, Wen S, Horne E, Oborn CJ, Langley R, Fidler IJ, Pettaway CA. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol 181(1):81-7, 1/2009.
17. Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, Siefker-Radther A, Pisters LL, Swanson DA, Dinney CP, Kamat AM. Outcome of patients with Bladder Cancer with pN+ Disease After Preoperative Chemotherapy and Radical Cystectomy. J Urol 73(1):147-52, 1/2009.
18. Babaian RJ, Donnelly B, Bahn D, Baust JG, Dineen M, Ellis D, Katz A, Pisters LL, Rukstalis D, Shinokara K, Thrasher JB. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol 180(5):1993-2004, 11/2008.
19. Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM. Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol 26(6):595-9, 11/2008.
20. Ward JF, Pagliaro LC, Pisters LL. Salvage Therapy for radiorecurrent prostate cancer. Curr Probl Cancer 32(6):242-71, 11/2008.
21. Pisters LL, Rewcastle JC, Donnelly BJ, Lugnani FM, Katz AE, Jones JS. Salvage prostate cryoablation initial results from the cryo on-line data registry. J Urol 180(2):559-63, 8/2008.
22. Jones JS, Rewcastle JC, Donnelly BJ, Lugnani FM, Pisters LL, Katz AE. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol 180(2):554-8, 8/2008.
23. Sanda MG, Rodney RL, Dunn MS, Michalski J, Sandler HM, Northhouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Kibel A, Pisters LL, Kuban DA, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT. Quality of Life and Satisfaction with Outcome Among Prostate Cancer Survivors and their Spouses. N Engl J Med 358(12):1250-61, 3/2008.
24. Spiess PE, Busby JE, Jordan JJ, Steinberg JR, Bassett RL, Davuluri R, Burt K, Troncoso P, Lee AK, Taylor SH, Pisters LL. Can Digital Rectal Examination or Transrectal Ultrasonography biopsy findings predict the side of nodal metastasis in prostate cancer? Urologic Oncology 26(1):25-30, 1/2008.
25. Kassouf W, Agarwal P, Herr HW, Munsell MF, Spiess PE, Brown GA, Pisters LL, Grossman HB, Dinney CP, Kamat AM. Lymph Node Density Is Superior to TNM Nodal Status in Predicting Disease-Specific Survival After Radical Cystectomy for Bladder Cancer: Analysis of Pooled Data from MDACC and MSKCC. Journal of Clinical Oncology 26:121-126, 1/2008.
26. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP III, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III Prevention Trial of Fenretinide in Patients with Resected Non-Muscle-Invasive Bladder Cancer. Clinical Cancer Research 14(1):224-229, 1/2008.
27. Leibovici D, Spiess PE, Heller L. Rodgriguez-Bigas M, Chang G, Pisters LL01/2008. Salvage Surgery for Locally Recurrent Prostate Cancer After Radiation Therapy: Tricks of the Trade". Urologic Oncology 26(1):9-16, 1/2008.
28. Shetty AM, Stafford RJ, Elliott AM, Kassouf W, Brown GA, Stephens LC, Tinkey PT, Bidaut L, Pisters LL, Hazle JD. Magnetic resonance imaging assessment of a convective therapy delivery paradigm in a canine prostate model. J Magn Reson Imaging 26(6):1672-7, 12/2007.
29. Spiess PE, Tannir NM, Brown GA, Liu P, Tu SM, Evans JG, Pisters LL. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. Urol 70(6):1173-8, 12/2007.
30. Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Viable Germ Cell Tumor at Post-Chemotherapy RPLND: Can We Predict Who’s at Risk of Progression? Cancer 110(12):2700-2708, www.cancer.org, 12/2007.
31. Pisters LL. Treatment failure after primary and salvage therapy for prostate cancer. Cancer 112(2):225-227, 11/2007.
32. Kassouf W, Brown GA, Shetty A, Hazle JD, Stafford RJ, Rosser CJ, Stephens C, Tinkey PT, Pisters LL. An in vivo orthotopic canine model to evaluate distribution of intraprostatic injectate: implications for gene therapy and drug delivery for prostate cancer. Urology 70(4):822-5, 10/2007.
33. Lebovici D, Kassouf W, Pisters LL, Pettaway CA, Wu X, Dinney CP, Grossman HB. Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology 70(3):473-6, 9/2007.
34. Black PC, Basin-Engquistk, Wang X, Swartz RJ, Eddings T, Matin SF, Swanson D, Wood CG, Pisters LL, Babaian RJ, Troncosco P, Pettaway CA. A Randomized Prospective Trial Evaluation Testerone Hemoglobin Kinetics and quality of life, during and after 12 months of Androgen Deprivation after Prostatectomy results from the Postoperative Adjuvant Androgen. BJU Int. 100(1):63-9, 7/2007.
35. Kamat AM, Dinney CPN, Gee JR, Millikan JE, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL. Micropapillary bladder cancer: A review of the M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110(1):62-7, 7/2007. e-Pub 7/2007.
36. Shinn EH, Basen-Engquist K, Thornton B, Spiess PE, Pisters LL. Health behaviors and depressive symptoms in testicular cancer survivors. Urol 69(4):748-753, Apr 2007, 4/2007.
37. Spiess PE, Lee AK, Busby JE, Jordan JJ, Hernandez M, Burt K, Troncoso P, Merriman KW, Pisters LL. Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome? BJU Int 99(2):321-5, 2/2007. PMID: 17155975.
38. Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol 177(6):2151-2156, 2007.
39. Efstathiou E, Troncoso P, Wen S, Do KA, Pettaway CA, Pisters LL, McDonnell TJ, Logothetis CJ. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 13(4):1224-1231, 2007.
40. Pisters LL, Brown G, Spiess PE. Inside the Genetic Heterogeneity of Renal Cell Carcinoma: Will the c-Met Proto-Oncogene Be the Next Therapeutic Target? Kidney Cancer Journal 5(1):23-27, 2007.
41. Pendleton J, Pisters LL, Nakamura K, Anai S, Rosser CJ. Neoadjuvant Therapy Before Radical Prostatectomy: Where Have We Been? Where Are We Going? Urol Oncol 25(1):11-18, 2007.
42. Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol 177(1):131-138, 2007.
43. De E, Pisters LL, Pettaway CA, Scott S, Westney OL. Salvage prostatectomy with bladder neck closure, continent catheterizable stoma and bladder augmentation: Feasibility and patient reported continence outcomes at 32 months. J Urol 177(6):2200-2204, 2007.
44. Spiess PE, Kassouf W, Brown GA, Kamat AM, Liu P, Gomez JA, Tu SM, Tannir NM, Pisters LL. Surgical management of growing teratoma syndrome: the M. D. Anderson Cancer Center experience. J Urol 177(4):1330-1334, 2007.
45. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int 98(6):1176-1180, 12/2006. PMID: 17125474.
46. Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M, Pettaway CA, Dinney CP, Pisters LL. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol 176(4(Pt1)):1463-1467, 10/2006. PMID: 16952661.
47. Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 107(7):1483-1490, 10/2006. PMID: 16944541.
48. Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer 107(7):1503-1510, 10/2006. PMID: 16944534.
49. Izawa JI, Busby JE, Morganstern N, Vakar-Lopez F, Scott SM, Pisters LL. Histological changes in prostate biopsies after salvage cryotherapy: effect of chronology and the method of biopsy. BJU Int 98(3):554-558, 9/2006. PMID: 16925753.
50. Strom SS, Kamat AM, Gruschkus SK, Gu Y, Wen S, Cheung MR, Pisters LL, Lee AK, Rosser CJ, Kuban DA. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer 107(3):631-639, 8/2006. PMID: 16802288.
51. Westney OL, Scott S, Wood C, Eddings T, Johnson MM, Taylor JM, McGuire E, Pisters LL. Suburethral sling at the time of radical prostatectomy in patients at high risk of postoperative incontinence. BJU Int 98(2):308-313, 8/2006. PMID: 16879670.
52. Rosser CJ, Kamat AM, Pendleton J, Robinson TL, Pisters LL, Swanson DA, Babaian RJ. Impact of fellowship training on pathologic outcomes and complication rates of radical prostatectomy. Cancer 107(1):54-59, 7/2006. PMID: 16708356.
53. Spiess PE, Lee AK, Leibovici D, Wang X, Do KA, Pisters LL. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer 107(2):275-280, 7/2006. PMID: 16770783.
54. Spiess PE, Leibovici D, Pisters LL. Surgery for locally advanced disease. Curr Urol Rep 7(3):209-216, 5/2006. PMID: 16630524.
55. Rosser CJ, Kamat AM, Wang X, Do KA, Naya Y, Hoover DC, Troncoso P, Sanches-Ortiz RF, Pisters LL. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy. Urology 67(4):769-773, 4/2006. PMID: 16584762.
56. Sabichi AL, Lee JJ, Taylor RJ, Thompson IM, Miles BJ, Tangen CM, Minasian LM, Pisters LL, Caton JR, Basler JW, Lerner SP, Menter DG, Marshall JR, Crawford ED, Lippman SM. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res 12(7(Pt1)):2178-2184, 4/2006. PMID: 16609032.
57. Taylor SH, Merriman KW, Spiess PE, Pisters L. Inadequacies of the current American Joint Committee on cancer staging system for prostate cancer. Cancer 106(3):559-65, 2/2006.
58. Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 109(2):198-204, 2006.
59. Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, Detry MA, Robinson TL, Pisters LL. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 175(5):1967, 2006. PMID: 16469571.
60. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 174(6):2186-2190, 12/2005. PMID: 16280761.
61. Rosser CJ, Kamat AM, Wang X, Do KA, Sanchez-Ortiz RF, Kuban DA, Lee AK, Cheung R, Chichakli R, Pisters LL. Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer? Urology 66(2):327-631, 8/2005. PMID: 16040084.
62. Kim J, Sun P, Lam YW, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, McDonnell TJ, Lieberman R, Logothetis C, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev 14(7):1697-1702, 7/2005. PMID: 16030104.
63. Ahrar K, Matin S, Wood CG, Wallace MJ, Gupta S, Madoff DC, Rao S, Tannir NM, Jonasch E, Pisters LL, Rozner MA, Kennamer DL, Hicks ME. Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes. J Vasc Interv Radiol 16(5):679-688, 5/2005. PMID: 15872323.
64. Leibovici D, Lee AK, Cheung RM, Spiess PE, Kuban DA, Rosser CJ, Shen Y, Yang Y, Chichakli R, Pisters LL. Symptomatic local recurrence of prostate carcinoma after radiation therapy. Cancer 103(10):2060-2066, 5/2005. PMID: 15822114.
65. Kamat AM, Carpenter SM, Czerniak BA, Pisters LL. Metastatic penile cancer in a young Caucasian male: impact of delayed diagnosis. Urol Oncol 23(2):130-131, 3/2005. PMID: 15869998.
66. Leibovici D, Pagliaro L, Rosser CJ, Pisters LL. Salvage surgery for bulky local recurrence of prostate cancer following radical prostatectomy. J Urol 173(3):781-783, 3/2005. PMID: 15711269.
67. Cheung R, Tucker SL, Lee AL, Dong L, Kamat A, Pisters LL, Kuban DA. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 61(1):14-19, 2005.
68. Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters LL, Kuban D. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 61(4):993-1002, 2005.
69. 86. Cheung R, Kamat AM, de Crevoisier R, Allen PK, Lee AK, Tucker SL, Pisters LL, Babaian RJ, Kuban D. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys 63(1):134-140, 2005.
70. Leibovici D, Kamat AM, Do KA, Pettaway CA, Ng CS, Evans RB, Rodriguez-Bigas M, Skibber J, Wang X, Pisters LL. Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer. Prostate 62:101-104, 2005. PMID: 15389800.
71. Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA, Millikan RE. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol 172:481-484, 8/2004. PMID: 15247709.
72. Rosser CJ, Kuban DA, Lee SJ, Levy LB, Pettaway C, Kamat AM, Chichakli R, Lee A, Cheung RM, Sanchez-Ortiz R, Pisters LL. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. J Natl Med Assoc 96:939-944, 7/2004. PMID: 15253325.
73. Kamat AM, Rosser CJ, Levy LB, Chichakli R, Lee AK, Cheung MR, Pisters LL. Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure. Urology 63:1132-1137, 6/2004. PMID: 15183966.
74. Rosser CJ, Tanaka M, Pisters LL, Tanaka N, Levy LB, Hoover DC, Grossman HB, McDonnell TJ, Kuban DA, Meyn RE. Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation. Cancer Gene Ther 11:273-279, 4/2004. PMID: 14765130.
75. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG, Do KA, Brisbay SM, Wang X, Hossan EA, Evans RB, Soto C, Jacobson MG, Parker K, Merritt JA, Steiner MS, Logothetis CJ. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 10:2587-2593, 4/2004. PMID: 15102659.
76. Rosser CJ, Tanaka N, Stafford RJ, Price RE, Hazle JD, Tanaka M, Kamat AM, Pisters LL. Feasibility to delineate distribution of solution injected intraprostatic using an ex-vivo canine model. Gene Ther Mol Biol 8:509-514, 2004.
77. Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Millikan RE. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 171:145-148, 2004. PMID: 14665863.
78. Kamat AM, Shock RP, Naya Y, Rosser CJ, Slaton JW, Pisters LL. Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology 63:46-50, 2004. PMID: 14751346.
79. Rosser CJ, Kuban DA, Levy LB, Pettaway CA, Chichakli R, Kamat AM, Sanchez-Ortiz RF, Pisters LL. Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy. J Urol 170:1856-1859, 11/2003. PMID: 14532792.
80. Kamat AM, Huang SF, Bermejo CE, Rosser CJ, Pettaway CA, Pisters PW, Guitreau DP, Pisters LL. Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 170:1868-1871, 11/2003. PMID: 14532795.
81. Sweeney P, Wood CG, Pisters LL, Slaton JW, Vaporciyan A, Munsell M, Carpenter S, Putnam J, Swisher SG, Walsh G, Swanson D, Dinney CP. Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol 21:327-333, 9/2003. PMID: 14670538.
82. Taylor N, Kelly JF, Kuban DA, Babaian RJ, Pisters LL, Pollack A. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 56:755-763, 7/2003. PMID: 12788182.
83. Bermejo CE, Pisters LL. Cryotherapy for prostate cancer. Expert Rev Anticancer Ther 3:393-401, 6/2003. PMID: 12820781.
84. Rosser CJ, Levy LB, Kuban DA, Chichakli R, Pollack A, Lee A, Pisters LL. Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostate. J Urol 169:2160-2165, 6/2003. PMID: 12771739.
85. Izawa JI, Morganstern N, Chan DM, Levy LB, Scott SM, Pisters LL. Incomplete glandular ablation after salvage cryotherapy for recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 56:468-472, 6/2003. PMID: 12738322.
86. Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, Grossman HB, Dinney CP, Swanson DA, Pisters LL. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 169:2113-2117, 6/2003. PMID: 12771730.
87. Rosser CJ, Reyes AO, Vakar-Lopez F, Levy LB, Kuban DA, Hoover DC, Lee AK, Pisters LL. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol Biol Phys 56:1-6, 5/2003. PMID: 12694817.
88. Siefker-Radtke AO, Gee J, Shen Y, Wen S, Daliani D, Millikan RE, Pisters LL. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol 169:1295-1298, 4/2003. PMID: 12629346.
89. Sexton WJ, Wood CG, Kim R, Pisters LL. Repeat retroperitoneal lymph node dissection for metastatic testis cancer. J Urol 169:1353-1356, 4/2003. PMID: 12629359.
90. Pisters LL. Salvage radical prostatectomy: refinement of an effective procedure. Semin Radiat Oncol 13:166-174, 4/2003. PMID: 12728446.
91. Rosser CJ, Kuban DA, Levy LB, Chichakli R, Pollack A, Lee AK, Pisters LL. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol 168:2001-2005, 11/2002. PMID: 12394695.
92. Sweeney P, El-Naggar AK, Lin SH, Pisters LL. Biological significance of c-met over expression in papillary renal cell carcinoma. J Urol 168:51-55, 7/2002. PMID: 12050491.
93. Izawa JI, Madsen LT, Scott SM, Tran JP, McGuire EJ, Von Eschenbach AC, Pisters LL. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol 20:2664-2671, 6/2002. PMID: 12039928.
94. Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer 94:2610-2617, 5/2002. PMID: 12173328.
95. Davis JW, Pisters LL, Doviak MJ, Donat SM. Early nasogastric tube removal combined with metoclopramide after postchemotherapy retroperitoneal lymph node dissection for metastatic testicular nonseminomatous germ cell tumor. Urology 59:579-583, 4/2002. PMID: 11927318.
96. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordonez NG, Troncoso P, Navone NM. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res 8:775-781, 3/2002. PMID: 11895908.
97. *Rosser CJ, Chichakli R, Levy LB, Kuban DA, Smith LG, Pisters LL. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation. J Urol 168:536-541, 2002.
98. Mian BM, Bhadkamkar N, Slaton JW, Pisters PW, Daliani D, Swanson DA, Pisters LL. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 167:65-70, 2002. PMID: 11743277.
99. Scott SM, Evans RB, Pisters LL. Prostate cancer rates decline. Physician Assistant 26:28-43, 2002.
100. Kent D, Gee JR, Amato RJ, Pisters LL. Successful management of metastatic urethral cancer with organ preservation. J Urol 166:2308, 12/2001. PMID: 11696764.
101. Giesler EJ, Gee JR, Reece GP, Pettaway CA, Pollock RE, Pisters LL. Cutaneous metastases of penile squamous cell carcinoma following en bloc resection of inguinal recurrence with immediate pedicle flap reconstruction. J Urol 166:1384-1385, 10/2001. PMID: 11547082.
102. Sexton WJ, Lance RE, Reyes AO, Pisters PW, Tu SM, Pisters LL. Adult prostate sarcoma: the M. D. Anderson Cancer Center Experience. J Urol 166:521-525, 8/2001. PMID: 11458058.
103. Lance RS, Dinney CP, Swanson D, Babaian RJ, Pisters LL, Palmer LJ, Grossman HB. Radical cystectomy for invasive bladder cancer in the octogenarian. Oncol Rep 8:723-726, 7/2001. PMID: 11410772.
104. Pisters LL, Wang XH, Chung LW, Hsieh JT. Differential expression of c-erb B2/neu, epidermal growth factor receptor, cytokeratin 8, and the prostatic steroid-binding protein gene in rat ventral prostate during postnatal development. Prostate 47:164-171, 5/2001. PMID: 11351345.
105. Izawa JI, Perrotte P, Greene GF, Scott S, Levy L, McGuire E, Madsen L, von Eschenbach AC, Pisters LL. Local tumor control with salvage cryotherapy for locally recurrent prostate cancer after external beam radiotherapy. J Urol 165:867-870, 3/2001. PMID: 11176488.
106. Izawa JI, Ajam K, McGuire E, Scott S, von Eschenbach AC, Skibber J, Pisters LL. Major surgery to manage definitively severe complications of salvage cryotherapy for prostate cancer. J Urol 164:1978-1981, 12/2000. PMID: 11061895.
107. Pisters LL, Westney OL, Scott SM, Swanson DA, Wood CG, Von Eschenbach AC, Dinney CP, McGuire EJ. Puburethral sling simultaneous with radical retropubic prostatectomy for patients at high risk for postprostatectomy incontinence. Prostate Cancer Prostatic Dis 3(S1):S34, 12/2000.
108. Pisters LL, English SF, Scott SM, Westney OL, Dinney CP, McGuire EJ. Salvage prostatectomy with continent catheterizable urinary reconstruction: a novel approach to recurrent prostate cancer after radiation therapy. J Urol 163:1771-1174, 6/2000. PMID: 10799179.
109. Sweeney P, Pisters LL. Ad5CMVp53 gene therapy for locally advanced prostate cancer--where do we stand? World J Urol 18:121-124, 4/2000. PMID: 10854146.
110. Pettaway CA, Pisters LL, Troncoso P, Slaton J, Finn L, Kamoi K, Logothetis CJ. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 18(5):1050-1057, 3/2000. PMID: 10694556.
111. Corral DA, Varma DG, Jackson EF, Amato RJ, Donat SM, Pisters LL. Magnetic resonance imaging and magnetic resonance angiography before postchemotherapy retroperitoneal lymph node dissection. Urology 55:262-266, 2/2000. PMID: 10688091.
112. Pisters LL Kuo W. Current status of prostate-specific antigen testing in the United States. Journal of Pelvic Surgery 6(5):273-283, 2000.
113. Corral DA, Cleary KR, Pisters LL. Renal cell carcinoma drop metastasis to the left spermatic vein in a patient with prior varicocele ligation. Journal of Pelvic Surgery 6:42-43, 2000.
114. Donat SM, Slaton JW, Pisters LL, Swanson DA. Early nasogastric tube removal combined with metoclopramide after radical cystectomy and urinary diversion. J Urol 162:1599-1602, 11/1999. PMID: 10524876.
115. Perrotte P, Tran J, McGuire EJ, Pisters LL. Effect of prior therapy on survival after salvage cryotherapy for recurrent prostate cancer. Prostate Cancer Prostatic Dis 2(S3):S25, 11/1999.
116. Pisters LL, Pettaway CA, Hossan E, Evans RE, Steiner MS, Wood CG, Troncoso P, McDonnell TJ, Fenstenmacher MJ, Logothetis CJ. Intraprostatic AD-p53 gene therapy followed by radical prostatectomy: feasibility and preliminary results. Prostate Cancer Prostatic Dis 2(S3):S27, 11/1999.
117. Pisters LL, Perrotte P, Scott SM, Greene GF, von Eschenbach AC. Patient selection for salvage cryotherapy for locally recurrent prostate cancer after radiation therapy. J Clin Oncol 17(8):2514-2520, 8/1999. PMID: 10561317.
118. Perrotte P, Litwin MS, McGuire EJ, Scott SM, von Eschenbach AC, Pisters LL. Quality of life after salvage cryotherapy: the impact of treatment parameters. J Urol 162:398-402, 8/1999. PMID: 10411046.
119. Levy DA, Cromeens DM, Evans R, Stephens LC, von Eschenbach AC, Pisters LL. Transrectal ultrasound-guided intraprostatic injection of absolute ethanol with and without carmustine: a feasibility study in the canine model. Urology 53(6):1245-1251, 6/1999. PMID: 10367863.
120. Pisters LL, Dinney CP, Pettaway CA, Scott SM, Babaian RJ, von Eschenbach AC, Troncoso P. A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer. J Urol 161:509-514, 2/1999. PMID: 9915437.
121. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 161:304-308, 1999. PMID: 10037428.
122. Nowroozi MR, Pisters LL. The Current Status of Gene Therapy for Prostate Cancer. Cancer Control 5(6):522-531, 11/1998. PMID: 10761101.
123. Greene GF, Pisters LL, Scott SM, Von Eschenbach AC. Predictive value of prostate specific antigen nadir after salvage cryotherapy. J Urol 160:86-90, 7/1998. PMID: 9628611.
124. Pisters LL, Troncoso P, Navone N. Prolonged survival with metastatic prostate cancer to bone. J Urol 159:210, 6/1998. PMID: 9598540.
125. Westney OL, Pisters LL, Pettaway CA, Tu SM, Pollack A, Dinney CP. Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J Urol 159:792-795, 3/1998. PMID: 9474150.
126. English SF, Pisters LL, McGuire EJ. The use of the appendix as a continent catheterizable stoma. J Urol 159:747-749, 3/1998. PMID: 9474139.
127. Slaton JW, Balbay MD, Levy DA, Pisters LL, Nesbitt JC, Swanson DA, Dinney CP. Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma. Urology 50(5):673-677, 11/1997. PMID: 9372873.
128. Pisters LL, el-Naggar AK, Luo W, Malpica A, Lin SH. C-met proto-oncogene expression in benign and malignant human renal tissues. J Urol 158:724-728, 9/1997. PMID: 9258068.
129. Chen ME, Pisters LL, Malpica A, Pettaway CA, Dinney CP. Risk of urethral, vaginal and cervical involvement in patients undergoing radical cystectomy for bladder cancer: results of a contemporary cystectomy series from M. D. Anderson Cancer Center. J Urol 157:2120-2123, 6/1997. PMID: 9146596.
130. Nesbitt JC, Soltero ER, Dinney CP, Walsh GL, Schrump DS, Swanson DA, Pisters LL, Willis KD, Putnam JB, Jr. Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Ann Thorac Surg 63:1592-1600, 6/1997. PMID: 9205155.
131. Pisters LL, von Eschenbach AC, Scott SM, Swanson DA, Dinney CP, Pettaway CA, Babaian RJ. The efficacy and complications of salvage cryotherapy of the prostate. J Urol 157:921-925, 3/1997. PMID: 9072600.
132. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 157:569-574, 2/1997. PMID: 8996359.
133. Cespedes RD, Pisters LL, von Eschenbach AC, McGuire EJ. Long-term followup of incontinence and obstruction after salvage cryosurgical ablation of the prostate: results in 143 patients. J Urol 157:237-240, 1997. PMID: 8976261.
134. Sarosdy MF, Pisters LL, Carroll PR, Benson MC, Moon TD, Lamm DL, Hudson MA, Lerner SP, Koch MO, Schellhammer PF. Bropirimine immunotherapy of upper urinary tract carcinoma in situ. Urology 48(1):28-32, 7/1996. PMID: 8693647.
135. Seigne JD, Pisters LL, von Eschenbach AC. Osteitis pubis as a complication of prostate cryotherapy. J Urol 156:182, 7/1996. PMID: 8648793.
136. Greene G, Pisters LL, von Eschenbach AC. “Modern” prostate cryotherapy. J Pelvic Surg 2(4):198-204, 1996.
137. Delworth MG, Pisters LL, Fornage BD, von Eschenbach AC. Cryotherapy for renal cell carcinoma and angiomyolipoma. J Urol 155:252-255, 1996. PMID: 7490847.
138. Tanguay S, Pisters LL, Lawrence DD, Dinney CP. Therapy of locally recurrent renal cell carcinoma after nephrectomy. J Urol 155:26-29, 1996. PMID: 7490850.
139. Pettaway CA, Pisters LL, Dinney CP, Jularbal F, Swanson DA, von Eschenbach AC, Ayala A. Sentinel lymph node dissection for penile carcinoma: the M. D. Anderson Cancer Center experience. J Urol 154:1999-2003, 12/1995. PMID: 7500444.
140. Kagan J, Stein J, Babaian RJ, Joe YS, Pisters LL, Glassman AB, von Eschenbach AC, Troncoso P. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 11:2121-2126, 11/1995. PMID: 7478532.
141. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LW. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 154:293-298, 7/1995. PMID: 7539865.
142. Kleinerman DI, Troncoso P, Lin SH, Pisters LL, Sherwood ER, Brooks T, von Eschenbach AC, Hsieh JT. Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. Cancer Res 55:1215-1220, 3/1995. PMID: 7533659.
143. Zhau HE, Pisters LL, Hall MC, Zhao LS, Troncoso P, Pollack A, Chung LW. Biomarkers associated with prostate cancer progression. J Cell Biochem Suppl 19:208-216, 1994. PMID: 7529853.
144. Kagan J, Pisters LL, Troncoso P, Joe YS, Parat JM, Babaian RJ, von Eschenbach AC. Genetic instability in microsatellite sequences in prostate cancer. Int J Oncology 5:921-924, 1994.
145. Bandyk MG, Zhao L, Troncoso P, Pisters LL, Palmer JL, von Eschenbach AC, Chung LW, Liang JC. Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Gene Chrom 9:19-27, 1994. PMID: 7507696.
146. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85(20):1657-1669, 10/1993. PMID: 7692074.
147. Pisters LL Wajsman Z. Use of predeposit autologous blood and intraoperative autotransfusion in urologic cancer surgery. Urology 40(3):211-215, 9/1992. PMID: 1523742.
148. Pisters LL Wajsman Z. A simple test for the detection of intraoperative rectal injury in major urological pelvic surgery. J Urol 148:354, 8/1992. PMID: 1635133.
149. Pisters LL, Tykochinsky G, Wajsman Z. Intravesical bacillus Calmette-Guerin or mitomycin C in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy. J Urol 146:1514-1517, 12/1991. PMID: 1942330.
150. Smallbone BW, Davies BJ, Noulty EJ, Pisters LL, Taylor NE, McDonald JW. Effects of verapamil on thromboxane synthesis and pulmonary hypertension in sheep. Clin Invest Med 9(3):145-9, 1986. PMID: 3757320.

Invited Articles

1. Leibovici D, Spiess PE, Lee AK, Pisters LL. Symptomatic Local Recurrence of Prostate Cancer After Radiation Therapy : Lessons Learned from 1006 Patients Treated at M. D. Anderson Cancer Center. The American Journal of Oncology Review 4(9):25-28, 2005.
2. Pisters LL. Editorial contribution to UrologyHealth.org. Received Silver Award from Consumer Health Publishers Association and Online Health Association. American Urological Association, 2004.
3. Huang S, Pisters LL. Cryotherapy for prostate cancer. UpToDate in Oncology 9(2):2001, 2001.
4. Pisters LL. The challenge of locally advanced prostate cancer. Semin Oncol 26(2):202-216, 1999. PMID: 10597731.
5. Pisters LL, Pettaway CA, Troncoso P, Finn LD, Scott SM, Logothetis CJ. Preliminary results of preoperative chemotherapy and hormonal therapy followed by radical prostatectomy for locally advanced prostate cancer. Prostate Cancer and Prostatic Diseases 1(1):15, 1998.
6. Nesbitt JC, Gregoric ID, Pisters LL. Renal cell carcinoma with Budd-Chiari syndrome. Contemporary Surgery 53(1):53-56, 1998.
7. Pisters LL, von Eschenbach AC. Technique, results, and complications of “modern” prostate cryotherapy. American Urological Association Update Series, Lesson 37 15:298-303, 1996.
8. Pisters LL, Westney L. The management of locally recurrent invasive bladder cancer following radical cystectomy. Semin Urol Oncol 14(2):112-119, 1996. PMID: 8734739.
9. Corral DA, Pisters LL, von Eschenbach AC. Treatment options for localized recurrence of prostate cancer following radiation therapy. Urol Clin North Am 23(4):677-684, 1996. PMID: 8948420.
10. Pisters LL, Babaian RJ. Evaluating screening tools for prostate cancer. Hospital Medicine:62-79, 1993.
11. Pisters LL Babaian RJ. The status of early prostate cancer detection. Cancer Bulletin 45(5):389-396, 1993.
12. Pisters LL, Babaian RJ. The status of early prostate cancer detection (Part 1). Hospital Medicine:18-23, 1993.

Editorials

1. Pisters LL. Commentary on Cryosurgical Ablation of the Prostate for Prostate Cancer: Background, Technique, and Results, in Pantuck AJ, Zisman A, Belldegrun. Management of Prostate Cancer Advances and Controversies. New York, Marcel Dekker:278-281, 2005.
2. Pisters LL. Prostate cancer--adjusting the tiller. J Urol 155:1678-1680, 1996. PMID: 8627852.
Other Articles
1. Spiess PE, Huang S, Pisters LL. Cryotherapy in prostate cancer. Uptodate (online medical book: http:www.uptodate.com). In Press.

Abstracts

1. Parker PA, Latini DM, Ward JF, Pettaway CA, Pisters LL, Matin SF, Frank SJ, Brown V, Kuban DA, Logothetis CJ, Kim J, Davis JW. Associations Between Uncertainty, Anxiety, and Quality of Life in Men with Prostate Cancer on Active Surveillance. Annals of Behavioral Medicine 37 (Suppl) 37, 03/2009, 3/2009.
2. Pettaway CA, Pisters LL, Troncoso P, Wang R, Brown GO, Busby JE, Spiess PE, Millikan RE, Logothetis CJ. Clinical aspects of the high risk neoadjuvant treatment model: Five year results. American Urological Association 2006 Annual Meeting, Atlanta, GA. J Urol 962:310, 2006.
3. Spiess PE, Brown GO, Pettaway CA, Gomez JA, Evans J, Kassouf W, Black P, Kamat AM, Pisters LLP. Malignant transformation of testicular teratoma: A chemoresistant phenotype. American Urological Association 2006 Annual Meeting, Atlanta, GA. J Urol 455:147, 2006.
4. Spiess PE, Kassouf W, Brown GO, Kamat AM, Gomez JA, Evans J, Pisters LL. MDACC experience in the clinical management of growing teratoma syndrome. American Urological Association 2006 Annual Meeting, Atlanta, GA. J Urol 448:145, 2006.
5. Hu JC, Wood DP, Andriole GL, Dunn RL, Dahl DM, Hollenbeck BK, Kibel AS, Saigal CS, Litwin MS, Pisters LL, Klein EA, Montie LE, Wei JT, Sanda MG. Perioperative quality care indicators of retropubic, laparoscopic, and robotic prostatectomy: Results from a national, multi-center, prospective cohort. American Urological Association 2006 Annual Meeting, Atlanta, GA. J Urol 1151:370, 2006.
6. Sanda MG, Dunn RL, Northouse L, Litwin MS, Hembroff L, Sandler HM, Jeff M, Klein EA, Saigal CS, Pisters LL, Kuban DA, Kaplan I, Wei JT. Prostate cancer physician performance measured by patient-reported ratings of practitioner manner/skill and by treatment-related adverse events. American Urological Association 2006 Annual Meeting, Atlanta, GA. J Urol 1605:517, 2006.
7. Spiess PE, Busby JE, Jordan J, Hernandez M, Troncoso P, Burt KL, Lee AK, Taylor SH, Merrimen KW, Bassett RR, Pisters LL. Radical prostatectomy for lymph node positive prostate cancer: The MDACC experience. American Urological Association 2006 Annual Meeting, Atlanta, GA. J Urol 966:311, 2006.
8. Spiess PE, Brown GO, Liu P, Evans J, Kamat AM, Pisters LL. Recurrence pattern and proposed surveillance protocol in patients following post-chemotherapy retroperitoneal lymph node dissection. American Urological Association 2006 Annual Meeting, Atlanta, GA. J Urol 595:192, 2006.
9. Sanda MG, Dunn RL, Arbor A, Saigal CS, Klein EA, Pisters LL, Michalski JM, Kibel AS, Madadevan A, Sandler HM, Kuban DA, Litwin MS, Wei JT, Arbor A. Association of race, cancer severity, pre-treatment quality of life, and patient optimism/pessimism with patient selection of primary prostate cancer treatment. American Urological Association 2005 Annual Meeting, San Antonio, TX 1671:453, 2005.
10. Kamat AM, Rosser CJ, Wen S, Cheung RM, Lee AK, Putman S, Pisters LL. Body mass index does not affect outcome for men undergoing external-beam radiotherapy for localized prostate cancer. American Urological Association 2005 Annual Meeting, San Antonio, TX 1033:280, 2005.
11. Spiess PE, Evans J, Kamat AM, Wood CG, Pettaway CA, Dinney CPN, Pisters LL. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection for testicular cancer: review of the University of Texas M. D. Anderson Cancer Center experience. American Urological Association 2005 Annual Meeting, San Antonio, TX 725:197, 2005.
12. Bochner BH, Uzzo RG, Sokoloff M, Pisters LL, Matin SF, Sanda MG, Arbor A, Colberg J, Wood CG , Konety BR, Penson DF. Current status of clinical trials in urothelial cancers: A summary from the ACOSOG GU working group. American Urological Association 2005 Annual Meeting, San Antonio, TX 1327:360, 2005.
13. Kamat AM, Gee JR, Grossman BH, Dinney CPN, Siefer-Radtke AO, Millikan RE, Swanson DA, Robinson TL, Pisters LL. Micropapillary transitional cell carcinoma of the bladder: A retrospective review of the experience with 100 consecutive patients. American Urological Association 2005 Annual Meeting, San Antonio, TX 1113:302, 2005.
14. Sanda MG, Dunn RL, Arbor A, Mahadevan A, Sandler HM, Arbor A, Saigal CS, Kuban DA, Michalski JM, Pisters LL, Klein EA, Kibel AS, Litwin MS, Hembroff L, Wei JT, Arbor A. Neoadjuvant hormone therapy (NHT) leads to immediate impairment of vitality/hormonal and sexual quality of life: Results of a multi-center prospective study. American Urological Association 2005 Annual Meeting, San Antonio, TX 824:223, 2005.
15. De E, Pisters LL, Pettaway CA, Scott SM, Westney OL. Salvage prostatectomy with bladder neck closure and continent catheterizable bladder augmentation: 31-month follow-up by patient report and incontinence symptom index. American Urological Association 2005 Annual Meeting, San Antonio, TX 283:78, 2005.
16. Kassouf W, Leibovici D, Zhou X, Dinney CPN, Barton GH, Siefer-Radtke AO, Pisters LL, Swanson DA, Kamat AM. Significance of lymph node positive disease in patients treated with neoadjuvant chemotherapy: Is adjuvant chemotherapy beneficial? American Urological Association 2005 Annual Meeting, San Antonio, TX 1317:358, 2005.
17. Leibovici D, Lee AK, Cheung RM, Kuban DA, Rosser CJ, Chichakli R, Pisters LL. Symptomatic local recurrence of prostate cancer after radiation therapy. American Urological Association 2005 Annual Meeting, San Antonio, TX 694:189, 2005.
18. Kamat AM, Gee JR, Dinney CPN, Grossman BH, Swanson DA, Millikan RE, Robinson TL, Pisters LL:. The case for early cystectomy in non-muscle-invasive micropapillary transitional cell carcinoma of the bladder. American Urological Association 2005 Annual Meeting, San Antonio, TX 915:247, 2005.
19. Leibovici D, Kassouf W, Kamat AM, Pisters LL, Pettaway CA, Dinney CPN. Transurethral tumor resection versus partial cystectomy for bladder preservation for muscle invasive cancer. American Urological Association 2005 Annual Meeting, San Antonio, TX 1119:303, 2005.
20. Tanaka M, Rosser CJ, Tanaka N, Grossman HB, Kuban DA, Meyn RE, Pisters LL. Adenoviral-mediated PTEN transgene expression sensitizes radio-resistant prostate cancer cell in vitro to radiation. American Urological Association 2003 Annual Meeting, Chicago, IL. J Urol 169:857A, 2003.
21. Kamat AM, Rosser CJ, Levy LB, Chichakli R, Pisters LL. Fluctuation of ³0.5 ng/ml in serum PSA more than 2 years after external-beam radiotherapy predicts for biochemical failure. American Urological Association 2003 Annual Meeting, Chicago, IL. J Urol 169:1719A, 2003.
22. Rosser CJ, Levy LB, Kuban DA, Chichakli R, Pollack A, Lee A, Pisters LL. Hazard rates of disease progression after external-beam radiotherapy for clinically localized carcinoma of the prostate. American Urological Association 2003 Annual Meeting, Chicago, IL. J Urol 169:695A, 2003.
23. Izawa JI, Morganstern N, Chan DM, Levy LB, Scott S, Pisters LL. Incomplete glandular ablation following salvage cryotherapy for recurrent prostate cancer following radiotherapy. American Urological Association 2003 Annual Meeting, Chicago, IL. J Urol 169:936A, 2003.
24. Siefker-Radtke AO, Dinney CP, Abrahams NA, Pisters LL, Grossman HB, Swanson DA, Millikan RE. Is there a role for pre-operative chemotherapy in small cell bladder carcinoma? The M. D. Anderson experience. American Urological Association 2003 Annual Meeting, Chicago, IL. J Urol 169:1300A, 2003.
25. Scott SM, Leibovich B, Izawa JI, Blute ML, Madsen L, von Eschenbach AC, Slezak JM, Zincke H, Pisters LL. A comparison of biochemical outcome following salvage prostatectomy or cryosurgery for locally recurrent prostate cancer after radiation therapy. South Central Section of the American Urological Association, 81st Annual Meeting, Colorado Springs, CO 33:172, 2002.
26. Sweeny P, Slaton JW, Munsell M, Carpenter S, Vaporciyan A, Swanson DA, Wood CG, Pisters L, Dinney CP. An analysis of prognostic factors for patients with renal cancer extending into the vena cava. American Urological Association 2002 Annual Meeting, Orlando, FL. J Urol 167:777A, 2002.
27. Huang S, Swanson D, Pisters L, von Eschenbach A, Babaian R, Chang D, Wood CG. Contralateral sural nerve grafting (SNG) after unilateral nerve sparing radical prostatectomy (RP) improves post-operative potency rates. American Urological Association 2002 Annual Meeting, Orlando, FL. J Urol 167:1365A, 2002.
28. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens C, Wood CG, Do K-A, Brisbay SM, Wang X, Hossan EA, Evans RB, Soto CP, Fenstermacher MJ, Parker K, Merritt JA, Steiner MS, Logothetis CJ. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. American Urological Association 2002 Annual Meeting, Orlando, FL. J Urol 167:1335A, 2002.
29. Slaton JW, Kedar D, Balbay MD, Dinney CP, Wood CG, Pisters LL, Swanson DA. Impact of rising rates of obesity on morbidity of radical nephrectomy. American Urological Association 2002 Annual Meeting, Orlando, FL. J Urol 167:782A, 2002.
30. Sweeney P, Millikan RE, Wood CG, Pettaway CA, Donat M, Grossman B, Pisters LL. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection (RPLND) in metastatic transitional cell carcinoma (TCC) of the bladder? American Urological Association 2002 Annual Meeting, Orlando, FL. J Urol 167:1117A, 2002.
31. Gee JR, Kent DS, Millikan RE, Dinney CP, Grossman HB, Pisters LL. Micropapillary bladder carcinoma: Preliminary results of BCG and neoadjuvant chemotherapy. American Urological Association 2002 Annual Meeting, Orlando, FL. J Urol 167:1031A, 2002.
32. Boelter CW, Pisters L, Gettman M, Sweeney P, Weaver A, Lohse C, Carpenter S, Dinney C, Cheville JC, Zincke H, Blute ML. Renal cell carcinoma with extension to the right atrium: Prognostic factors and long-term follow-up of the Mayo Clinic and M. D. Anderson experience. American Urological Association 2002 Annual Meeting, Orlando, FL. J Urol 167:785A, 2002.
33. Min R, Sexton WJ, Wood CG, Pisters LL. Repeat retroperitoneal lymph node dissection for metastatic testis cancer. South Central Section of the American Urological Association, 81st Annual Meeting, Colorado Springs, CO 128:265, 2002.
34. Rosser CJ, Kuban DA, Levy LB, Chichakli R, Pollack A, Lee A, Pisters LL. The PSA “bounce” phenomena after external beam radiation for clinically localized prostate cancer. American Urological Association 2002 Annual Meeting, Orlando, FL. J Urol 167:1556A, 2002.
35. Scott SM, Izawa JI, Morgenstern N, Chan DM, Levy LB, Pisters LL. Variables associated with incomplete glandular ablation following salvage cryotherapy for recurrent prostate cancer following radiotherapy. South Central Section of the American Urological Association, 81st Annual Meeting, Colorado Springs, CO 35:174, 2002.
36. Pisters L, Leibovich B, Izawa J, Blute M, Madsen L, Scott S, von Eschenbach A, Slezak J, Zincke H. A comparison of biochemical outcome following salvage prostatectomy or cryosurgery for locally recurrent prostate cancer after radiation therapy. American Society for Therapeutic Radiology and Oncology 43rd Annual Meeting, San Francisco, CA 2135 (#2135), 2001.
37. Sexton WJ, Lance RE, Reyes AO, Pisters PWT, Tu S-M, Pisters LL. Adult prostate sarcomas: The M. D. Anderson Cancer Center experience. South Central Section of the American Urological Association, 80th Annual Meeting, Austin, TX 13:147, 2001.
38. Pisters LL, Pettaway CA, McDonnell TJ, Troncoso P, Brisbay SM, Wood CG, Stephens LC, Hossan EA, Evans RB, Fenstermacher MJ, Parker K, Merritt JA. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. South Central Section of the American Urological Association, 80th Annual Meeting, Austin, TX 14:148, 2001.
39. Kedar D, Izawa J, Tamboli P, Ainslie N, Eddings T, Babaian RJ, Dinney CPN, Pisters LL, Pettaway CA. Intraoperative lymphatic mapping (IOLM) for squamous penile cancer: The M. D. Anderson Cancer Center prospective experience. American Urological Association 96th Annual Meeting, Anaheim, CA. J Urol 165:711A, 2001.
40. Pisters LL, McDonnell TJ, Troncoso P, Brisbay S, Hossan E, Pettaway C, Wood C, Evans R, Steiner M, Merritt J, Logothetis C. Intraprostatic Ad-p53 gene therapy induces apoptosis in locally advanced adenocarcinoma of the prostate. American Society of Clinical Oncology 37th Annual Meeting, San Francisco, CA. Proceedings of the American Society of Clinical Oncology 20:699A, 2001.
41. Izawa JI, Madsen L, Scott S, von Eschenbach A, Pisters L. Long term follow-up of salvage cryotherapy for locally recurrent prostate cancer following radiation therapy. American Urological Association 96th Annual Meeting, Anaheim, CA. J Urol 165:1359A, 2001.
42. Leibovich BC, Zincke H, Blute ML, Slezak JM, Izawa J, Madsen L, Scott S, von Eschenbach AC, Pisters LL. Recurrent prostate cancer after radiation therapy: Salvage prostatectomy versus salvage cryosurgery. American Urological Association 96th Annual Meeting, Anaheim, CA. J Urol 165:1595A, 2001.
43. Kim R, Sexton WJ, Wood CG, Pisters LL. Repeat retroperitoneal lymph node dissection for metastatic testis cancer. American Urological Association 96th Annual Meeting. Anaheim, CA. J Urol 165:628A, 2001.
44. Izawa J, Pisters LL, Madsen L, Scott S, von Eschenbach AC. Salvage cryotherapy for locally recurrent prostate cancer following radiation therapy: Variables impacting patient survival. American Society of Clinical Oncology 37th Annual Meeting, San Francisco, CA. Proceedings of the American Society of Clinical Oncology 20:760A, 2001.
45. Scott S, Izawa J, Pisters LL, Madsen L, von Eschenbach AC. Salvage cryotherapy for locally recurrent prostate cancer following radiation therapy: Variables impacting patient survival. South Central Section of the American Urological Association, 80th Annual Meeting, Austin, TX 20:154, 2001.
46. Rosser CJ, Smith LG, Chichakli R, Levy LB, Pollack A, Kuban DA, Pisters L. The effects of age on biochemical disease progression in men with carcinoma of the prostate treated with external beam irradiation. J Urol 165:1363A, 2001.
47. Pisters LL, Westney OL, Scott S, Swanson DA, McGuire EJ. Pubourethral sling simultaneous with radical retropubic prostatectomy for patients at high risk for postprostatectomy incontinence. South Central Section of the American Urological Association 79th Annual Meeting, Montreal, Quebec, Canada 87:215, 2000.
48. English SF, Scott SM, Pisters LL, McGuire EJ. The development of continence following radical prostatectomy for adenocarcinoma of the prostate. American Urological Association 95th Annual Meeting, Atlanta, GA. J Urol 163:1291A, 2000.
49. Daliani DD, Logothetis CJ, Pettaway CA, Meyers CA, Pisters LL, Coursen C, Davies K, Troncoso P, Reyes A. TNP-470 therapy preceding radical prostatectomy (RP): A model for assessment of safety and biologic activity of angiogenesis inhibitors. American Society of Clinical Oncology 36th Annual Meeting, New Orleans, LA. Proceedings of the American Society of Clinical Oncology 19:376A, 2000.
50. Perrotte P, Tran J, McGuire EJ, Pisters LL. Effect of prior therapy on survival after salvage cryotherapy for recurrent prostate cancer. Prostate Cancer Prostatic Dis 2(3):S25, 11/1999. PMID: 12496804.
51. Pisters LL, Pettaway CA, Hossan E, Evans R, Steiner MS, Wood CG, Troncoso P, McDonnell TJ, Fenstenmacher MJ, Logothetis CJ. Intraprostatic AD-p53 gene therapy followed by radical prostatectomy: feasibility and preliminary results. Prostate Cancer Prostatic Dis 2(3):S27, 11/1999. PMID: 12496806.
52. Logothetis CJ, Hossan E, Pettaway CA, Evans R, Steiner MS, Wood CG, Troncoso P, McDonnell TJ, Fenstenmacher MJ, Pisters LL. AD-p53 intraprostatic gene therapy preceding radical-prostatectomy (RP): An in vivo model for targeted therapy development. . J Urol 161:1142A, 1999.
53. Logothetis CJ, Hossan E, Evans R, Pettaway CA, Steiner MS, Gingrich J, Wood CG, Troncoso P, McDonnell TJ, Proksch S, Doerksen L, Merritt J, Fenstenmacher MJ, Pisters LL. Ad5CMV-p53 intraprostatic gene therapy preceding radical prostatectomy (RP): An in vivo model for targeted therapy development. American Society of Clinical Oncology 35th Annual Meeting, Atlanta, GA. Proceedings of the American Society of Clinical Oncology 18:1203A, 1999.
54. Pisters LL, English SF, Dinney CPN, McGuire EJ. Continent catheterizable urinary reconstruction in patients undergoing salvage prostatectomy. South Central Section of the American Urological Association 78th Annual Meeting, Santa Fe, NM 38:158, 1999.
55. Pettaway CA, Jularbal FE, Babaian RJ, Dinney CPN, Pisters LL. Intraoperative lymphatic mapping to detect inguinal metastases in penile carcinoma: Results of a pilot study. American Urological Association 94th Annual Meeting, Dallas, TX. J Urol 161:612A, 1999.
56. Pisters LL, Pettaway CA, Troncoso P, Finn LD, Slaton JW, Logothetis CJ. Preoperative chemotherapy (CHT) and hormonal therapy (AA) followed by radical prostatectomy (RP) for locally advanced prostate cancer (PCA). American Society of Clinical Oncology 35th Annual Meeting, Atlanta, GA. Proceedings of the American Society of Clinical Oncology 18:1212A, 1999.
57. Pettaway CA, Pisters LL, Troncoso P, Finn LD, Slaton JW, Logothetis CJ. Preoperative chemotherapy (CHT) and hormonal therapy (AA) followed by radical prostatectomy (RP) for locally advanced prostate cancer (PCA). American Urological Association 94th Annual Meeting, Dallas, TX. J Urol 161:1293A, 1999.
58. Tran JP, McGuire EJ, Greene GF, Westney OL, Perrotte P, Scott SM, von Eschenbach AC, Pisters LL. Salvage cryotherapy for recurrent prostate cancer following radiation therapy: The effect of prior therapy on patient survival. American Urological Association 94th Annual Meeting, Dallas, TX. J Urol 161:676A, 1999.
59. von Eschenbach AC, Perrotte P, Greene GF, Scott S, Tran JP, Pisters LL. Salvage cryotherapy for recurrent prostate cancer following radiation therapy: Variables impacting local tumor control. American Urological Association 94th Annual Meeting, Dallas, TX. J Urol 161:1381A, 1999.
60. Pisters LL, Perrotte P, Greene GF, Scott SM, Tran JP, von Eschenbach AC. Salvage cryotherapy for recurrent prostate cancer following radiation therapy: variables impacting local tumor control. South Central Section of the American Urological Association 78th Annual Meeting, Santa Fe, NM 37:157, 1999.
61. Pisters LL, English SF, Dinney CPN, McGuire EJ. Salvage prostatectomy with continent catheterizable urinary reconstruction: A novel approach to recurrent prostate cancer following radiation therapy. . J Urol 161:1293A, 1999.
62. Swanson DA, von Eschenbach AC, Babaian RJ, Dinney CPN, Pisters LL, Pettaway CA. Is retroperitoneal lymph node dissection (RLND) alone optimal or sufficient therapy for clinical stage I nonseminomatous germ cell testicular tumors (NSGCTT) at high risk for relapse? American Urological Association 93rd Annual Meeting, San Diego, CA. J Urol 159:179A, 1998.
63. Pisters LL, Corral DA, Varma DG, Jackson EF, Amato RJ, Donat SM. Magnetic resonance imaging and magnetic resonance angiography prior to post-chemotherapy retroperitoneal lymph node dissection. American Urological Association 93rd Annual Meeting, San Diego, CA. J Urol 159:182A, 1998.
64. Pisters LL, Pettaway CA, Troncoso P, Finn LD, Scott SM, Logothetis CJ:. Preliminary results of preoperative chemotherapy and hormonal therapy followed by radical prostatectomy (RP) for locally advanced prostate cancer (PCA). South Central Section of the American Urological Association 77th Annual Meeting, Mexico 70:180, 1998.
65. McGuire EJ, English SF, Scott S, Pisters LL. The development of continence following radical prostatectomy for adenocarcinoma of the prostate. American Urological Association 93rd Annual Meeting, San Diego, CA. J Urol 159:230A, 1998.
66. Inoue K, Slaton JW, Perrotte P, El-Naggar AK, Pisters LL, Swanson DA, Dinney CPN. The relationship of hepatocyte growth factor receptor (C-MET) to metastasis and progression in primary and metastatic renal cell carcinoma (RCC). American Urological Association 93rd Annual Meeting, San Diego, CA. . J Urol 159:754A, 1998.
67. Pisters LL, Levy DA, Cromeens DM, Stephens LC, von Eschenbach AC. Transrectal ultrasound-guided intraprostatic injection of absolute ethanol with and without carmustine: a feasibility study in the canine model. South Central Section of the American Urological Association 77th Annual Meeting, Cancun, Mexico 41:151, 1998.
68. Pisters LL, El-Naggar AK, Luo W, Malpica A, Lin S-H. C-met proto-oncogene expression in benign and malignant human renal tissues. American Urological Association 92nd Annual Meeting, New Orleans, LA. J Urol 157:1080A, 1997.
69. Pisters LL. Case Presentation - Twenty-one-year-old man with primary retroperitoneal germ cell tumor. South Central Section of the American Urological Society 76th Annual Meeting, Bermuda. J Urol 70:75, 1997.
70. Morgenstern N, Pisters LL, Ro JY, Batts P, Ayala A, von Eschenbach AC. Histologic changes over time after salvage prostate cryotherapy. American Urological Association 92nd Annual Meeting, New Orleans, LA. J Urol 157:903A, 1997.
71. Greene GF, Pisters LL, Scott SM, von Eschenbach AC. Predictive value of prostate specific antigen (PSA) nadir following salvage cryotherapy. American Urological Association 92nd Annual Meeting, New Orleans, LA. J Urol 157:1633A, 1997.
72. Pisters LL, El-Naggar AK, Weiping L, Malpica A, Lin S-H. The relationship between C-met proto-oncogene expression and grade in human renal cell carcinoma. South Central Section of the American Urological Association 76th Annual Meeting, Bermuda. J Urol 70:192, 1997.
73. Westney OL, Dinney CPN, Pisters LL, Pollack A, Millikan R, Pettaway CA. Therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. American Urological Association 92nd Annual Meeting, New Orleans, LA. J Urol 157:994A, 1997.
74. Sarosdy MF, Pisters LL, Carroll PR, Benson MC, Moon TD, Lamm DL, Hudson MA, Lemer SP, Koch MO, Graham SD, Schellhammer PF. Bropirimine is active against upper tract cytology positive for transitional cell cancer (TCC). American Urological Association 91st Annual Meeting, Orlando, FL. J Urol 155:729A, 1996.
75. Kleinerman DI, Troncoso P, Pisters LL, Navone NM, Hsieh JT, Logothetis CJ, von Eschenbach AC, Sleddens HFBM, Schroder FH, Trapman J. Expression and structure of the androgen receptor in bone metastases of hormone refractory prostate cancer. American Urological Association 91st Annual Meeting, Orlando, FL. J Urol 155:1254A, 1996.
76. Greene GF, Pisters LL, Troncoso P, Dinney CPN, von Eschenbach AC. Feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer. 51st Annual Meeting of the Canadian Urological Association, Victoria, BC. Can J Urol 3(2):59A, 1996.
77. Pisters LL, Troncoso P, Dinney CPN, von Eschenbach AC. Feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer. American Urological Association 91st Annual Meeting, Orlando, FL. J Urol 155:989A, 1996.
78. Cespedes RD, Pisters LL, von Eschenbach AC, Diaz E, McGuire EJ. Long term follow-up of incontinence after salvage cryosurgical ablation of the prostate: results in 143 patients. American Urological Association 91st Annual Meeting, Orlando, FL. J Urol 155:589A, 1996.
79. von Eschenbach AC, Scott SM, Swanson DA, Babaian RJ, Dinney CPN, Pettaway CA, Pisters LL. Quality of life after salvage cryotherapy for locally recurrent prostate cancer. American Urological Association 91st Annual Meeting, Orlando, FL. J Urol 155:506A, 1996.
80. Chen ME, Malpica A, Dinney CP, Pisters LL. Risk of urethral, vaginal, and cervical involvement in patients undergoing radical cystectomy for bladder cancer: A retrospective review of patients at M. D. Anderson Cancer Center. American Urological Association 91st Annual Meeting, Orlando, FL. J Urol 155:1263A, 1996.
81. Pisters LL, Scott SM, Swanson DA, Babaian RJ, Dinney CPN, Pettaway CA, von Eschenbach AC. The use of pretreatment factors to predict PSA outcome following salvage cryotherapy. J Urol 77:199, 1996.
82. Pisters LL, Scott SM, Swanson DA, Babaian RJ, Dinney CPN, Pettaway CA, von Eschenbach AC. Which patients with locally recurrent prostate cancer can be cured by salvage cryotherapy? American Urological Association 91st Annual Meeting, Orlando, FL. J Urol 155:1343A, 1996.

Book Chapters

1. Leibovici D, Spiess PE, Pisters LL. Rectal Wall Invasion of Locally Advanced Prostate Cancer: Comparison of Magnetic Resonance Imaging with Transrectal Ultrasound. In: Cancer Imaging. Ed(s) Hayat MA. Elsevier Science/Academic Press: New Jersey. In Press.
2. Spiess PE, Leibovici D, Pisters LL. Surgery for Locally Advanced Disease. In: Current Urology Reports. Ed(s) Kaplan SA. Current Science Inc. Philadelphia. In Press.
3. Lam JS, Pisters LL, Belldegrun AS. Cryotherapy for Prostate Cancer. In: Urology. 3, Ninth. Ed(s) Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ. Campbell-Walsh: Philadelphia, PA, 3032-3052, 2007.
4. Redman BG, Hurwitz M, Spiess PE, Pisters LL. Urothelial and Kidney Cancers. In: Cancer Management: A Multidisciplinary Approach, 10. Ed(s) Pazzur R, Coia L, Hoskins W, Wagman L. CMP Healthcare Medica: New York, 423-440, 2007.
5. Rosser CJ, Tanaka N, Stafford RJ, Price RE, Hazle JD, Tanaka M, Kamat AM, Pisters LL. Feasibility to delineate distribution of solution injected intraprostatic using an ex-vivo canine model. In: Gene Therapy and Molecular Biology. Ed(s) Boulikas T, Vougiouka M. Gene Therapy Press: Athens Greece, 509-514, 2005.
6. Mian B Pisters LL. Treatment of locally recurrent prostate cancer. In: Urology, Pearls of Wisdom. Ed(s) DA Levy. Boston Medical Publishing Corp: Boston, 282-287, 2001.
7. Scott S Pisters LL. Genitourinary cancers. In: Primary Care Oncology. Ed(s) K Boyer, M Ford, A Judkins, B Levin. W. B. Saunders: Philadelphia, 157-174, 1999.
8. Dinney CPN, Pisters LL, von Eschenbach AC. Cryo-ablation for prostate cancer. In: Comprehensive Textbook of Genitourinary Oncology. Ed(s) NJ Vogelzang, PT Scardino, WU Shipley, DS Coffey. Williams & Wilkins: Baltimore, 828-837, 1998.
9. Greene G, Pisters LL, von Eschenbach AC. Cryoablation of prostate cancer. In: Topics in Clinical Urology--Techniques for Ablation of Benign and Malignant Prostate Tissue. Ed(s) JA Smith Jr, DF Milam. Algaku-Shoin, 189-206, 1996.
10. Pisters LL von Eschenbach AC. Cryoablation for prostate cancer. In: Advances in Urology. 8. Ed(s) EJ McGuire, David Bloom, WF Catalona, LI Lipshultz. Mosby Year Book, Inc: Chicago, 97-116, 1995.
11. von Eschenbach AC Pisters LL. Current surgical techniques in urology. In: Current Surgical Techniques in Urology. 7 (Issue 6). Ed(s) CA Olsson. Medical Publications, Inc: Delaware, 1995.
12. Pisters LL Cohen MS. Reoperation for extrinsic ureteral obstruction (including retroperitoneal fibrosis) . In: Reoperative Urology. Ed(s) MI Resnick and MS Cohen. Little, Brown and Co, 75-86 (Chapter 9), 1995.
13. Pisters LL, Waisman Z. Salvage surgery following full-dose radiation therapy for prostate cancer. In: Atlas of Surgical Oncology. Ed(s) KI Bland, CP Karakousis, EM Copeland III. W. B. Saunders Company: Philadelphia, 605-615 (Chapter 21), 1995.
14. Pisters LL Wajsman Z. Surgery for invasive bladder cancer. In: Cancer Surgery. Ed(s) RJ Mckenna, GP Murphy. Lippincott: Philadelphia, 673-694, 1993.
15. Pisters LL, Hsieh JT, Bandyk MG, Zhau HE, Johnson DE. The molecular analysis of extracellular matrix associated gene expression in mouse skin treated with an 830 nm low power laser. In: Laser Applications in Medicine and Surgery. Ed(s) G Galletti, L Bolognani, G Ussia. Monduzzi Editore: Bologna, Italy, 171-174, 1992.

Manuals, Teaching Aids, Other Teaching Publications

1. Pisters LL. Audio Series – “Topics in Urology Audio Series,” Sponsored by the American Urological Association Education and Research, Inc.® Office of Education. 7, 2. Oakstone Medical Publishing, 2006.
2. Pisters LL. Audio Series – “The AUA’s Topics in Urology Audio Series,” Sponsored by the American Urological Association Education and Research, Inc.® Office of Education. 5, 8. Oakstone Medical Publishing, 2004.
3. Pisters LL. Postgraduate Course – “Biological Basis for Application of Mechanism-Based Therapy in Prostate Cancer,” American Urological Association 2003 Annual Meeting, Chicago, IL, 2003.
4. Pisters LL. Postgraduate Course – “Management and Treatment of Advanced Carcinoma of the Prostate,” American Urological Association 95th Annual Meeting, Orlando, FL, 2002.
5. Pisters LL. Postgraduate Course – “Management and Treatment of Advanced Carcinoma of the Prostate,” American Urological Association 95th Annual Meeting, Atlanta, GA, 2000.
6. Pisters LL. Postgraduate Course – “Rising Prostate-specific Antigen Level After Local Therapy for prostate cancer: Patient evaluation and treatment options.” American Society of Clinical Oncology 36th Annual Meeting, New Orleans, LA, 2000.
7. Pisters LL. Postgraduate Course -- “Management and Treatment of Advanced Carcinoma of the Prostate,” American Urological Association 94th Annual Meeting, Dallas, TX, 1999.
8. Pisters LL. Postgraduate Course -- “Management and Treatment of Advanced Carcinoma of the Prostate,” American Urological Association 93rd Annual Meeting, San Diego, CA, 1998.
9. Pisters LL. Postgraduate Course -- “Management and Treatment of Advanced Carcinoma of the Prostate,” American Urological Association 92nd Annual Meeting, New Orleans, LA, 1997.
10. Pisters LL. Director, Postgraduate Course -- "Cryoablation of the Prostate," American Urological Association 91st Annual Meeting, Orlando, FL, 1996.
11. Pisters, LL, von Eschenbach AC. Technique, results, and complications of ‘modern’ prostate cryotherapy.” American Urological Association Update Series, Lesson 37. 15, 298-303, 1996.

Grant & Contract Support

Title: The Behavioral Effects of Religiosity/Spirituality in Coping with Cancer
Funding Source: Charles A. Dana Foundation
Role: Principal Investigator
Duration: 2000 - 2002
 
Title: The Distribution of Hepatocyte Growth Factor/Scatter and Its Splicing Variants in Benign and Malignant Human Prostate Tissues
Funding Source: Prostate Cancer Research Program
Role: Principal Investigator
Duration: 1997
 
Title: Clinical Oncology Career Development Award
Funding Source: American Cancer Society (ACS)
Role: Principal Investigator
Duration: 1994 - 1997
 
Title: Phase III Study of Oral Bropirimine Versus Intravesical BCG in Adult Patients with BCG-Naive Bladder Carcinoma in Situ
Funding Source: The Upjohn Company
Role: Principal Investigator
Duration: 1994 - 1996
 
Title: The Role of Hepatocyte Growth Factor/Scatter Factor as a Panacrine Accelerator of Human Prostate Cancer Progression
Funding Source: Physician's Referral Service
Role: Principal Investigator
Duration: 1994 - 1995

Last updated: 7/9/2013